This document is a quarterly report submitted by the Executive Office of Health and Human Services to state committees regarding the Children's Medical Security Plan for the period from October 1, 2024, through December 31, 2024. It provides statistical data on the program's performance, noting that 87,730 children were eligible for coverage at the end of the quarter. The report details financial expenditures totaling approximately $11.7 million, which covered medical, dental, and pharmacy services for about 38,500 active members. Additionally, it outlines policy changes effective January 1, 2025, where premiums were removed for families earning up to 300% of the federal poverty level and all copayments were eliminated for all members.
This bill empowers the Health Policy Commission to investigate whether nonprofit hospitals are setting drug prices that are unreasonable or excessive. Upon receiving a referral, the commission can require hospitals to submit detailed information about their pricing methods, including how they calculate markups and how they treat drugs acquired under the 340B program. While the bill mandates the disclosure of specific pricing data, it includes strong confidentiality protections to prevent hospitals from revealing trade secrets or sensitive financial details. If the commission finds a price is too high, it will issue a public report with findings and recommendations, which may then trigger an independent investigation by the Attorney General. Ultimately, the legislation aims to increase transparency in hospital drug pricing without directly mandating specific price reductions.
This bill caps the out-of-pocket cost for insulin at $100 per 30-day supply for all patients, regardless of insulin type or prescription amount. It requires pharmaceutical companies with Medicaid rebate agreements to offer free 30-day insulin supplies to individuals urgently needing insulin (with less than 7 days' supply) who meet income criteria (≤400% of federal poverty level) and lack private drug coverage. Eligible individuals must provide proof of financial need and have a prescription. The cap applies to all insurers, manufacturers, and government programs covered under the bill, ensuring consistent cost limits without requiring additional coverage.
H 4944 allows pharmacists to dispense insulin in emergency situations without immediate prescription authorization. It defines an "emergency situation" as one where a patient cannot quickly obtain a doctor's approval, and requires pharmacists to use their professional judgment to determine if insulin is essential to prevent harm. The bill limits emergency insulin dispensing to a 30-day supply (or standard unit size if larger) and prohibits repeat dispensing to the same patient more than once every six months. This directly affects patients facing urgent insulin needs and pharmacists who may provide this emergency care under these specific guidelines. The law amends multiple sections of state law to include this emergency access provision.
H 4956 requires health insurance plans to cover clinician-administered drugs (outpatient prescriptions typically given in clinics or hospitals, like IV therapies) without extra costs or restrictions. It prohibits insurers from charging patients higher copays, denying coverage, or forcing them to use specific pharmacies when getting these drugs from their chosen provider or pharmacy. The bill also bans insurers from limiting coverage based on where the drug is dispensed or reducing payments to providers who source drugs from non-network pharmacies. This directly affects patients seeking these treatments, healthcare providers, and health benefit carriers. Insurers may offer but cannot mandate home infusion services or external infusion sites.
By Representative Sullivan-Almeida of Abington, a petition (accompanied by bill, House, No. 1330) of Alyson M. Sullivan-Almeida relative to pharmacy benefit managers reimbursements to pharmacies in the Commonwealth. Financial Services.
By Representative Silvia of Fall River, a petition (accompanied by bill, House, No. 2965) of Alan Silvia relative to providing prescription drug cost reimbursements to certain retirees. Public Service.
By Mr. Tarr, a petition (accompanied by bill, Senate, No. 830) of Bruce E. Tarr for legislation to preserve community pharmacies by conducting audits on contracts for pharmacy services. Financial Services.
This bill (HD 3446) allows eligible retired state employees and their Medicare-eligible dependents to enroll in health insurance plans purchased through the individual Medicare marketplace. It requires health reimbursement arrangements (HRAs) for these retirees to cover the costs of the lowest-cost Medicare Supplement Plan 1 and Part D prescription drug coverage in Massachusetts. The bill mandates that HRAs provide minimum annual funding equal to 50% of the sum of these two costs (based on annual rates set by the state). This change directly affects retired state employees and their Medicare-eligible family members who previously had limited options for supplemental coverage.
This bill requires pharmacy benefit managers (PBMs) in Massachusetts to follow specific rules when setting reimbursement rates for pharmacies. PBMs must ensure drugs on their cost lists are therapeutically equivalent, widely available from wholesalers, and not obsolete. Pharmacies can appeal underpayments through a formal process, with PBMs required to respond within 7 business days and adjust rates if appeals are upheld. The law directly affects pharmacies and PBMs, preventing PBMs from reimbursing pharmacies less than what they pay their own affiliated pharmacies for identical services.
